A high-performance gene chip platform for detecting genetic markers from circulating tumor cells  by Lin, Shiu-Ru et al.
Biomarkers and Genomic Medicine (2013) 5, 12e17Available online at www.sciencedirect.com
journal homepage: www.j -bgm.comREVIEW ARTICLE
A high-performance gene chip platform for detecting
genetic markers from circulating tumor cellsShiu-Ru Lin a,b,*, Ming-Yii Huang c,d, Ming-Sung Chang ea School of Medical and Health Sciences, Fooyin University, Kaohsiung, Taiwan
bDepartment of Medical Research, Fooyin University Hospital, Pingtung, Taiwan
cDepartment of Radiation Oncology, Kaohsiung Medical University Hospital, Cancer Center, Kaohsiung, Taiwan
dDepartment of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan
eDepartment of Surgery, Fooyin University Hospital, Pingtung, Taiwan
Received 3 April 2013; received in revised form 3 May 2013; accepted 6 May 2013
Available online 22 June 2013KEYWORDS
circulating tumor
cells;
colorimetric
membrane array;
gene chip;
weighted enzymatic
chip array* Corresponding author. Division of
Pingtung County 928, Taiwan.
E-mail address: srlin@ms2.hinet.n
2211-4254/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.gmbhs.2Abstract Diagnosis of and therapy for early-stage tumors has the potential to decrease
morbidity and mortality among patients with such malignancies. Although promising advances
in imaging technology and other diagnostic modalities have been achieved, evidence that pri-
mary cancers begin shedding neoplastic cells into the circulation at an early stage is accumu-
lating. Specifically, approximately 106 cells are shed daily per gram of tumor. Thus, circulating
tumor cells (CTCs) are a potential source for the noninvasive and early diagnosis of cancers.
Several studies have indicated that a preoperative detection of micrometastases may reflect
the transient shedding of tumor cells, metastatic potential, or residual disease, but that post-
operative micrometastases are likely to indicate minimal residual disease. Such neoplastic
cells may be present in the bloodstream in very low numbers and would be difficult to detect
by conventional methods. In this article, we introduce a highly sensitive gene chip analysis
method, developed from a colorimetric membrane array into a weighted enzymatic chip array,
to detect the gene clusters of CTCs. This gene chip method provides a fast and accurate anal-
ysis of gene clusters, with performance that is substantially better than that of traditional
biochemical examinations. The development of this gene chip solves the problem of costs
and artifacts that hampers traditional detection methods, and thus marks an important mile-
stone in the field of clinical diagnosis.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
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Gene chip to detect circulating tumor cells 13Introduction
cancer.13Circulating tumor cells
Circulating tumor cells (CTCs) are cells that are present in
the circulating blood of cancer patients and have the an-
tigenicity and genetic characteristics of the primary
tumor.1 Many studies have reported that, even in the early
stages of a cancer or when the tumor is very small, such
cancer cells may shed into the bloodstream or lymphatic
system. A study by Folkman et al found that active angio-
genesis to provide nutrients to a tumor is observable when
the tumor grows to a size of 2 mm in diameter.2 At that
point, tumor cells can enter the circulation, leading to
micrometastases. A study by Chang et al reported that
about 106 cancer cells per gram of tumor are shed into the
circulating blood every day.3 Because blood samples are
easy to collect, methods using peripheral blood samples as
specimens to detect whether CTCs are present in patients
are the most sensitive, accurate, and relatively noninvasive
auxiliary methods to assist in the early clinical diagnosis of
cancer.
Currently, there are many biotechnologies that can
detect CTCs in the bloodstream. These techniques include
immunohistochemical staining,4 flow cytometry,5 the
reverse transcriptase polymerase chain reaction (RT-PCR),6
and the CellSearch system (Veridex LLC, Raritan, NJ, USA).7
However, these methods have their shortcomings and lim-
itations. For example, immunohistochemical staining
methods cannot accurately determine the number of
circulating cancer cells in the blood of cancer patients.
Flow cytometry cannot describe the cell morphology of the
CTCs and requires further immunohistochemical staining
for confirmation,8e10 causing an increase in time and
expense for cancer detection that cannot meet the clinical
requirements of effectiveness. CellSearch system, a US
Food and Drug Administration-approved CTC test for met-
astatic breast, prostate, and colorectal cancer, is based on
a combination of immunomagnetic labeling and automated
digital microscopy. Its detection limit is one CTC per 7.5 mL
blood. Moreover, the anti-EpCAM antibody-based enrich-
ment strategy does not confer tissue-type specificity, and
the analysis requires specific equipment to perform it.11
Cancer genetic markers
With advances in molecular biology techniques, not only
have the genetic changes and molecular mechanisms
involved in various carcinogenic and transfer mechanisms
been elucidated, but clinically early diagnosis and prog-
nostic evaluation have also become simpler and easier by
detecting specific genetic markers of the cancer tissues.
Therefore, this has become an important direction of
development in the early diagnosis of cancer by using
cancer-specific target genes and changes in gene expres-
sion, for example in DNA sequence variants and mRNA
expression, as biomarkers for the differential diagnosis of
cancer.12 In addition, scientific evidence argues for the
existence of CTCs in patients with early cancer. Therefore,
this has become an important trend in cancer diagnosis and
treatment in terms of developing the detection of specialgenetic markers of CTCs to assist in the early diagnosis ofGenetic testing
Two well-known methods, RT-PCR and real-time quantita-
tive PCR, are highly sensitive methods that can detect ge-
netic markers of CTCs.14e16 However, these techniques can
detect only one type of genetic molecule at one time, which
is the greatest limitation of these techniques in clinical
applications.17 Due to the heterogeneity and characteristics
of simultaneous variation in multiple genetic molecules in
cancer cells, methods using multiple genetic markers can
improve the sensitivity and specificity of cancer detection
compared to methods using a single marker.18,19Gene chip operation platform
Gene chips, when implanted with a probe for multiple ge-
netic markers, can simultaneously detect several, dozens,
or even hundreds of genetic markers in one test. Through
analysis by specific software, an evaluation of the overall
experimental results for all markers can be provided to
greatly improve test accuracy in clinical application.20e22
Gene chips have the advantages of being fast and accu-
rate, and can be used to analyze large numbers of tests;
therefore, this approach is very convenient in investigating
the association between diseases and genomic changes.
Wang et al used a method combining suppression sub-
tractive hybridization and cDNA microarray chips to investi-
gate changes in all genes involved in the carcinogenic
pathway from colorectal hyperplastic polyps to colorectal
cancer.23 They successfully identified 71 genes specific for
colorectal cancer as diagnosticmarkers and obtained patents
in Taiwan (No. I278519), the USA (No. US 7575928), and the
European Union (No. 04 003 301.1). In order to implement the
clinical application of specific gene groups, it is necessary to
develop andestablish a gene chip detection platform that has
high sensitivity, high performance, and low cost so that it can
be efficiently used in clinical detection.Colorimetric membrane array
Traditionally, microarrays use glass carriers and fluorescent
labeling. Although this method has excellent sensitivity, it
is not always convenient in terms of operation. In addition,
its biggest drawbacks are expensive reagents and costly
equipment necessary for the related analysis.24,25 In order
to detect multiple genetic markers with a simple, conve-
nient, fast and low-cost method, Lin et al, in 2005, first
used a nylon membrane carrier to replace the glass carrier,
and digoxigenin cDNA labeling to replace the fluorescent
labeling.26 They successfully established a low-cost and
easy-to-operate colorimetric membrane array (CLMA) that
was patented in Taiwan (No. I287581; Fig. 1). There are
dozens of publications reporting clinical experimental re-
sults pertaining to the related technology platform,
including for gastric cancer, colorectal cancer, breast can-
cer, and lung cancer.26e30
Figure 1 The operating procedure for colorimetric membrane array (CLMA) used digoxigenin (DIG) for cDNA labeling and nitro
blue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) for the chromogenic reaction to detect circulating tumor cells
(CTCs) in the patient’s peripheral blood.
14 S.-R. Lin et al.Weighted chemiluminescent membrane array
Although CLMA contributes to the popularity of genetic
testingmarket, its clinical application in cancer diagnosis still
has considerable room for improvement in terms of its
sensitivity and specificity. The chemiluminescent analysis
platform was developed to meet this need (Fig. 2).28,29 The
best intensity value for each gene is calculated by the linear
value of the chemiluminescent emission. This process ismore
objective and accurate than readings based on the color
concentration in the CLMA. This method can also be widely
used in96-well real-timePCRanddetectionof genetic targets
on the chip. In addition, for the final results, weighting was
applied to the calculation based on the importance of eachFigure 2 The operating procedure of weighted chemiluminesc
chemiluminescent reaction, and a weighted calculation in which th
gene’s involvement in diseases. Through the weighted calculation,
the chip procedure. CCD, charge-coupled device.gene’s involvement indiseases.Thisweightedcalculationcan
increase the accuracy of detection by the chip method.31,32Weighted enzymatic chip array
The chemiluminescent chip detection platform can assist
with more precise clinical diagnosis, but it is difficult to
popularize due to its costly equipment, reagents, and
consumables. Therefore, Hsiung et al combined the ad-
vantages of CLMA and weighted chemiluminescent mem-
brane array (WCHMA) to use biotin cDNA labeling,
enzymatic chromogenic reaction, and gene-weighted
calculation to establish a new operation platform ofent membrane array included cDNA labeling with biotin, a
e weighted score was defined based on the importance of each
the total weighted value was obtained to interpret the result of
Figure 3 The operating procedure of weighted enzymatic chip array included RNA purification by magnetic beads, cDNA labeling
with biotin, an enzymatic chromogenic reaction, and a weighted calculation to interpret the results from the chip.
Gene chip to detect circulating tumor cells 15weighted enzymatic chip array (WEnCA; Fig. 3).33 This
technique has outstanding characteristics of low-cost and
high-sensitivity.
In recent years, after a series of studies, it has been
confirmed that WEnCA has a sensitivity, specificity, and
accuracy above 92%.33e35 This is a breakthrough compared
to the sensitivity and accuracy of the previous method of
CLMA. WEnCA also has an equivalent specificity to that of
WCHMA. In general, WEnCA significantly improves the effi-
cacy of the detection platform, which is of great help inTable 1 Related publication and clinical evaluation results of
nescent membrane array (WCHMA), and weighted enzymatic chip
Literature Sensitivity Sp
CLMA
Chen et al26 83.7 90
Yeh et al28 88.8 87
Chen et al29 80.6 83
Chen et al36 86.0 88
Wu et al27 89.1 91
Wang et al37 94.3 94
Chong et al38 89.0 84
Wang et al39 88.9 90
Yen et al40 84.4 95
Tsao et al31 83.1 96
WCHMA
Tsao et al31 92.9 94
Yang et al32 90.2 94
WEnCA
Hsiung et al33,34 WEnCA-Chipball 89 94
WEnCA- manual 93 94
Huang et al35 94.7 93
Data are presented as % unless otherwise specified.clinical applications. Related literature and clinical evalu-
ation results are shown in Table 1.26e29,31e40Discussion
Although the assessment of CTCs is currently not a routine
procedure in the clinical management of cancer, many
studies have demonstrated its potential clinical application
as a useful biomarker for cancer diagnosis,41 determinationcolorimetric membrane assay (CLMA), weighted chemilumi-
array (WEnCA) platform.
ecificity Accuracy Cancer type (n)
.9 86.8 Colorectal cancer (39)
Lung cancer (19)
Breast cancer (10)
Adrenal tumors (8)
.8 88.2 Colorectal cancer (80)
.8 d Breast cancer (102)
.0 d Breast cancer (92)
.3 90.3 Gastric cancers (64)
.0 d Colorectal cancer (88)
.0 d Nonsmall cell lung cancer (70)
.4 90.0 Colorectal adenoma (70)
.3 90.8 Colorectal cancer (76)
.4 91.9 Nonsmall cell lung cancer (209)
.2 93.8 Nonsmall cell lung cancer (209)
.9 93.5 Colorectal cancer (168)
92 Nonsmall cell lung cancer (209)
94
.5 97.0 Colorectal cancer (105)
16 S.-R. Lin et al.of therapy outcome,13,42 and evaluation of prognostic fac-
tors43,44 in various cancers such as breast cancer,45 colo-
rectal cancer,46 lung cancer,39 pancreatic cancer,47 and
hepatocellular carcinoma.48
As mentioned earlier, WEnCA combines the advantages
of CLMA and WCHMA for the detection of CTCs. The WEnCA
gene chip detection technique has the following advan-
tages in clinical application: (1) high efficiencydchanges in
a large number of gene groups on the chip can be analyzed
simultaneously; (2) high accuracydthe sensitivity and
specificity of genetic testing can be improved simulta-
neously; (3) low costdlarge-scale equipment is not needed
because of the simplified steps, so the cost of detection can
be effectively reduced; (4) conveniencedeither general
laboratory operations or automation systems can be
applied to effectively reduce human error and the time
required for detection; and (5) high applicabilitydit can be
applied as a core technology for any study involving the
investigation of clinical diseases or basic research pertain-
ing to changes in gene expression.
High-performance detection technologies using gene
chips such as CLMA and WEnCA are detection platforms with
favorable results as assessed by a long-term analysis of their
clinical uses. Although the long operating time,multiple-step
procedure, and higher technical threshold are the bottle-
necks that still need to be overcome, the high accuracy and
high sensitivity indeed give this detection platform a high
clinical application value. We believe that these platforms
can definitely be popularized in the future to become the
most important detection technologies for genetic markers.References
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